Therachon is Granted Orphan Drug Designation by US FDA for Apraglutide for the Treatment of Short Bowel Syndrome

Second Orphan Drug Designation for apraglutide, a next-generation, synthetic GLP-2 analog with a potentially best-in-class profileBASEL, Switzerland, Jan. 16, 2019 -- (Healthcare Sales & Marketing Network)-- Therachon AG ("Therachon"), a cl...Biopharmaceuticals, Gastroenterology, FDA
Therachon, apraglutide, short bowel syndrome, achondroplasia